Intensified Lipid-Lowering Therapy in Coronary Heart Disease: Is the Concept of “the Lower the Better” Evidence Based?
- Erland Erdmann MD, FESC, FAHA, FACC
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Lipid-lowering therapy for secondary and primary prevention of atherosclerotic coronary heart disease is well established [1, 2]. All current guidelines support statin treatment in high-risk patients, especially in type 2 diabetes patients . Apparently, the beneficial results of statin therapy suggest an almost linear relationship between the degree of low-density lipoprotein cholesterol (LDL-C) reduction and the relative risk of cardiovascular disease. This is, however, controversial because all recommendations are based on clinical trials that examined fixed doses of statins. In none of the trials has a gradual titration of lipid therapy to the proposed LDL goals been examined. In this respect, valuable results are given by the Heart Protection Study (HPS) trial, as all participants in this trial received 40 mg of simvastatin before randomization. The investigators measured each participant’s biological response to statin therapy. By giving all study participants a brief period of ...
- European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601 -1610
- Guidelines on the management of stable angina pectoris. Eur Heart J (2006) 27, 1341–1381
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J (2007) 28, 88– 136
- Echt, et al.: Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo - The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788. CrossRef
- Barter P, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122. CrossRef
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
- Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
- Kastelein J, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443. CrossRef
- Villines TC, et al.: The ARBITER 6-HALTS Trial. J Am Coll Cardiol 2010, 55:2721–2726. CrossRef
- Berneis K, et al.: Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010, 31:1633–1639. CrossRef
- Winkler K, et al.: Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest 2009, 39:463–470. CrossRef
- Stojakovic T, et al.: Differential effects of fluvastatin alone or in combination with ezetimibe on lipoproteinsubfractions in patients at high risk of coronary events. Eur J Clin Invest 2010, 40:187–194. CrossRef
- Intensified Lipid-Lowering Therapy in Coronary Heart Disease: Is the Concept of “the Lower the Better” Evidence Based?
Current Treatment Options in Cardiovascular Medicine
Volume 13, Issue 1 , pp 1-3
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Author Affiliations
- 1. Klinik für Kardiologie, Angiologie, Pneumologie und Internistische Intensivmedizin, Herzzentrum der Universität zu Köln, Kerpener Str. 62, 50937, Köln, Germany